Optima Health PLC reported a 60% increase in first-half revenue to £96 million, driven by its acquisition of PAM Healthcare and growth in core operations. The company secured significant new contracts, including deals with HM Revenue and Customs and the Home Office, contributing to a strong pipeline of opportunities. Net debt decreased to £70.4 million, reflecting focus on cash generation and debt reduction. Optima expects to meet full-year market expectations and will publish interim results by December 2026.
Optima Health revenue growth is the subject, with Pluang market data providing context. For readers following health-sector stocks, 92 of 150 US stocks rose and 53 fell today. Notable movers include ROIV at USD 34.72 (+3.55%), IONS at USD 44.39 (+3.38%), and FLNA at USD 0.68 (-3.31%) with 100% buy orders. Data is as of Oct 20, 2026 14:11 WIB.
VINCI's subsidiary Cobra IS secured a €165 million contract to construct a cooling plant for a major data center campus in the Iberian Peninsula. The project involves installing mechanical, electrical, and plumbing systems for 126 dry coolers, which ...
VINCI's subsidiary Cobra IS secured a €165 million contract to build the cooling system for a massive data center campus in the Iberian Peninsula. The project includes installing mechanical, electrical, and plumbing equipment for 126 air cooling unit...
Basilea Pharmaceutica announced new clinical and activity data for its antifungal drugs fosmanogepix and isavuconazole, as well as the antibiotic ceftobiprole, to be presented at IDWeek 2026 in Washington D.C. Highlights include pediatric data from f...
Gainsight introduced its AI-native services business, Atlas, which manages over $75 million in annual recurring revenue (ARR) by handling long-tail customer renewals with AI agents and human managers. The company also announced a shift to value-based...
Traders poured $54.6 million into the Direxion Daily S&P Biotech Bull 3X ETF (LABU) on October 14, 2026, marking the largest inflow relative to its $597 million size. LABU offers triple daily exposure to biotech stocks, making it highly volatile and ...
